Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 775 Shares of Company Stock

Beta Bionics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Beta Bionics insider Mark Hopman sold 775 shares on November 16 at an average of $16.22, worth about $12,570. He retained 54,143 shares after the sale.
  • Hopman has made several additional sales in recent months, including transactions of more than 30,000 shares in September. Beta Bionics shares were down 2.6% to $14.33 in Wednesday trading.
  • The company reported quarterly revenue of $35.51 million and a loss of $0.52 per share, slightly better than analysts’ estimate. Analysts’ consensus rating is “Moderate Buy,” with a $23.69 average price target.
  • Five stocks to consider instead of Beta Bionics.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 775 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $16.22, for a total value of $12,570.50. Following the completion of the sale, the insider directly owned 54,143 shares of the company's stock, valued at $878,199.46. This represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Mark Hopman also recently made the following trade(s):

  • On Monday, October 26th, Mark Hopman sold 821 shares of Beta Bionics stock. The stock was sold at an average price of $20.00, for a total transaction of $16,420.00.
  • On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25.
  • On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The shares were sold at an average price of $18.96, for a total transaction of $7,015.20.
  • On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total transaction of $619,581.27.
  • On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20.
  • On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Stock Down 2.6%

NASDAQ BBNX traded down $0.39 during midday trading on Wednesday, hitting $14.33. The company had a trading volume of 1,376,418 shares, compared to its average volume of 1,176,370. The firm has a fifty day simple moving average of $18.29 and a two-hundred day simple moving average of $14.86. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The stock has a market cap of $779.12 million, a price-to-earnings ratio of -7.79 and a beta of 3.44.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. The business had revenue of $35.51 million during the quarter. As a group, equities analysts predict that Beta Bionics, Inc. will post -2.04 earnings per share for the current year.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the second quarter worth approximately $52,340,000. Eversept Partners LP boosted its holdings in shares of Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock worth $14,177,000 after acquiring an additional 736,576 shares in the last quarter. Bank of America Corp DE acquired a new position in shares of Beta Bionics in the 2nd quarter worth approximately $8,566,000. Perceptive Advisors LLC grew its position in Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company's stock worth $8,446,000 after acquiring an additional 240,000 shares during the last quarter. Finally, Bruce & Co. Inc. bought a new stake in Beta Bionics during the 1st quarter worth approximately $5,518,000.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BBNX. Leerink Partners boosted their price objective on Beta Bionics from $24.00 to $27.00 and gave the company an "outperform" rating in a research report on Monday, September 14th. Piper Sandler reaffirmed an "overweight" rating and issued a $24.00 target price (up from $20.00) on shares of Beta Bionics in a research report on Wednesday, October 28th. TD Cowen lifted their price target on shares of Beta Bionics from $18.00 to $21.00 and gave the stock a "hold" rating in a research note on Wednesday, October 28th. Wall Street Zen lowered shares of Beta Bionics from a "hold" rating to a "strong sell" rating in a report on Saturday, October 31st. Finally, Truist Financial increased their price objective on shares of Beta Bionics from $23.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, September 24th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.69.

View Our Latest Analysis on BBNX

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user's body weight and adjusts insulin delivery based on glucose readings.

Recommended Stories

Insider Buying and Selling by Quarter for Beta Bionics (NASDAQ:BBNX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines